Resistance grows to Recordati's private equity takeover - pharmaphorum
Why now
Thesis: Private equity takeover resistance is company-specific governance story.
Catalyst to watch: Any revised bid or board decision.
Main risk: Limited read-through to broader healthcare.
Why it matters
Resistance to a private equity takeover of a European pharma company is a company-specific governance story with limited read-through to broader healthcare or market pricing.
Sources
- googlenews · news.google.com · 2026-09-14 10:01 UTC